PSY101 - LONG-TERM COST-EFFECTIVENESS OF EUROFIT VERSUS WAITING LIST

A.P. Finch, S. Wyke, S. Kolovos, H. van der Ploeg, F. van Nassau, J.E. Bosmans

Research output: Contribution to journalArticleAcademic

Abstract

Objectives: Male obesity is on the rise, but few men take part in weight loss programmes. One reason for this could be the absence of gender‐sensitised interventions for men. This study aims to investigate the long‐term cost‐effectiveness of EuroFIT, a gender sensitised weight loss and healthy living programme for male football (soccer) fans, compared to waiting list. Methods: A Markov model was developed to represent the benefits of physical activity in reducing the incidence of 4 chronic health conditions (colorectal cancer, type 2 diabetes, coronary heart disease and stroke) and mortality. The model employed a 5‐year time horizon from a societal perspective and measured health gains in terms of quality adjusted life years (QALYs). Data was obtained from 4 pragmatic randomised controlled trials evaluating EuroFIT conducted in England, Netherlands, Portugal and Norway, epidemiological and cohort studies, and reviews of the literature. Parameter uncertainty was assessed using deterministic and probabilistic sensitivity analysis. Uncertainty was presented using cost‐effectiveness acceptability curves (CEACs). A lifetime horizon was used in a sensitivity analysis. Results: Preliminary evidence suggests that over a 5‐year time horizon the average cost per participant for the EuroFIT group is €10 lower than for the waiting list, while the average QALY gain is 0.014. CEACs show that the probability of EuroFIT being cost‐effective compared to waiting list is 95% at 10,000 € per QALY. Sensitivity analysis suggests that EuroFIT is €16 cheaper and results in a gain of 0.2 QALYs compared to waiting list over a lifetime horizon with a 90% probability of being cost‐effective at 13,000 € per QALY. Conclusions: This analysis shows that EuroFIT,a gender sentisied weight loss and healthy living programme, is cost‐effective at 5 years and over a lifetime as compared to waiting list.
Original languageEnglish
Pages (from-to)S453
JournalValue in Health
Volume21
DOIs
Publication statusPublished - 24 Dec 2018

Cite this